Geron Corporation (GERN)
-NasdaqGS 1.12 0.00(0.00%) May 24, 4:00PM EDT
| Prev Close: | 1.12 |
|---|
| Open: | 1.11 |
|---|
| Bid: | 1.04 x 2000 |
|---|
| Ask: | 1.16 x 2000 |
|---|
| 1y Target Est: | 1.50 |
|---|
| Beta: | 2.03 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.09 - 1.13 |
|---|
| 52wk Range: | 0.91 - 2.99 |
|---|
| Volume: | 392,723 |
|---|
| Avg Vol (3m): | 750,544 |
|---|
| Market Cap: | 146.08M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.49 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- GERON CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecurityEDGAR Online(Fri, May 24)
- 3 Merger and Acquisitions Stock Stories For a Thursday Appraisalat Wall St. Cheat Sheet(Thu, May 23)
- Geron's CEO Hosts 2013 Annual Shareholder Meeting (Transcript)at Seeking Alpha(Wed, May 22)
- Scientists create human stem cells through cloningat Reuters(Wed, May 15)
- GERON CORP FinancialsEDGAR Online Financials(Fri, May 10)
- GERON CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 3)
- Geron Narrows Loss; Cuts JobsZacks(Mon, Apr 29)
- Geron Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, Apr 26)
- Geron Earnings Call scheduled for 8:30 am ET todayCCBN(Fri, Apr 26)
- GERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Costs Associated with Exit or DisposalEDGAR Online(Thu, Apr 25)
- Geron Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Thu, Apr 25)
- Geron Updates Imetelstat Development Strategy, Including Progress of Investigator-Sponsored Study in MyelofibrosisThomson Reuters ONE(Thu, Apr 25)
- Stem Cells: Dreamers, Fools, And The Valley Of Deathat Seeking Alpha(Thu, Apr 25)
- Q1 2013 Geron Earnings Release - After Market CloseCCBN(Thu, Apr 25)
- Geron to Present at the Needham Healthcare ConferenceThomson Reuters ONE(Wed, Apr 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 65.80 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.30 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -0.75 |
|---|
Business Summary
Geron Corporation, a biopharmaceutical company, develops therapies for cancer. Its clinical development product candidate includes Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of advanced non-small cel...
View More